Poster: TAPBOOST technology: Novel Technology to Enhance the Production of Therapeutic Recombinant Proteins Through Protein Folding System
Presenter: Akinori Hishiya, Boston Strategics Corporation
About: Although protein folding is very important for the production of therapeutic proteins, due to the complicated protein folding system, the technology to specifically promote protein folding of targeted proteins has not been successful yet. TAPBOOST technology is a novel technology which exploits the cellular protein folding system. In TAPBOOST technology, a proprietary protein called “TAPBOOSTER” is expressed together with the therapeutic protein. Selective TAPBOOSTER can be designed to target any kind of protein. The TAPBOOSTER targeted protein is 1) functional, 2) stable, and 3) easy to secrete. All these effects significantly enhance the production of the targeted therapeutic protein. TAPBOOSTER has successfully enhanced the production of many therapeutic recombinant proteins such as Humira® (9 folds), DP12® anti-IL8 antibody (8 folds), Enbrel® (6 folds), and Avastin® (4 folds). Importantly, TAPBOOST technology is very effective especially to proteins with protein folding problem such as IL13Ralpha2-Fc (Fc fusion protein with IL13 receptor alpha2 truncated form). By using TAPBOOST technology, the productivity of IL13Ralpha2-Fc was drastically improved more than 20 folds. The unique mechanism of TAPBOOST technology enables this technology to combine with any other existing technologies to enhance the production of therapeutic protein with synergistic effect.
Share this article with your social network, just click below to share now!
|
|
No comments :
Post a Comment